SCM
JAZZ icon

Superstring Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Superstring Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40,893
Closed -$5.39M – 52
2025
Q3 		$5.39M Sell
40,893
-3,214
-7% -$385K 5.31% 6
2025
Q2 		$4.68M Buy
+44,107
New +$4.79M 5.54% 7

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Superstring Capital Management's JAZZ Position: Q4 2025 in Review

Superstring Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2025, closing a stake of 40,893 shares — an estimated $5.39M sold.

Superstring Capital Management first reported a position in JAZZ in Q2 2025 and held it in 2 quarters. The position peaked at $5.39M in Q3 2025. 573 funds tracked by Wall St. Rank hold JAZZ as of Q4 2025.

  • Superstring Capital Management reported no remaining Jazz Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Superstring Capital Management sold 40,893 Jazz Pharmaceuticals shares in Q4 2025, an estimated $5.39M.
  • Superstring Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Superstring Capital Management's Jazz Pharmaceuticals position peaked at $5.39M in Q3 2025.
  • 573 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2025.

Based on Superstring Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.